Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 21:9:290.
doi: 10.1186/1471-2407-9-290.

The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters

W Al Sarakbi  1 , W Sasi, W G Jiang, T Roberts, R F Newbold, K Mokbel
Affiliations

The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters

W Al Sarakbi et al. BMC Cancer. .

Abstract

Background: SET domain containing protein 2 (SETD2) is a histone methyltransferase that is involved in transcriptional elongation. There is evidence that SETD2 interacts with p53 and selectively regulates its downstream genes. Therefore, it could be implicated in the process of carcinogenesis. Furthermore, this gene is located on the short arm of chromosome 3p and we previously demonstrated that the 3p21.31 region of chromosome 3 was associated with permanent growth arrest of breast cancer cells. This region includes closely related genes namely: MYL3, CCDC12, KIF9, KLHL18 and SETD2. Based on the biological function of these genes, SETD2 is the most likely gene to play a tumour suppressor role and explain our previous findings. Our objective was to determine, using quantitative PCR, whether the mRNA expression levels of SETD2 were consistent with a tumour suppressive function in breast cancer. This is the first study in the literature to examine the direct relationship between SETD2 and breast cancer.

Methods: A total of 153 samples were analysed. The levels of transcription of SETD2 were determined using quantitative PCR and normalized against (CK19). Transcript levels within breast cancer specimens were compared to normal background tissues and analyzed against conventional pathological parameters and clinical outcome over a 10 year follow-up period.

Results: The levels of SETD2 mRNA were significantly lower in malignant samples (p = 0.0345) and decreased with increasing tumour stage. SETD2 expression levels were significantly lower in samples from patients who developed metastasis, local recurrence, or died of breast cancer when compared to those who were disease free for > 10 years (p = 0.041).

Conclusion: This study demonstrates a compelling trend for SETD2 transcription levels to be lower in cancerous tissues and in patients who developed progressive disease. These findings are consistent with a possible tumour suppressor function of this gene in breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier disease free survival analysis depending on the expression of SETD2: .00 = low levels. 1.00 = high levels. P = 0.120
Figure 2
Figure 2
Kaplan-Meier overall survival analysis depending on the expression of SETD2: .00 = low levels. 1.00 = high levels. P = 0.232
See this image and copyright information in PMC

References

    1. Sun XJ, Wei J, Wu XY, Hu M, Wang L, Wang HH. et al.Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J Biol Chem. 2005;280(42):35261–71. doi: 10.1074/jbc.M504012200. - DOI - PubMed
    1. Cuthbert AP, Bond J, Trott DA, Gill S, Broni J, Marriott A. et al.Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J Natl Cancer Inst. 1999;91(1):37–45. doi: 10.1093/jnci/91.1.37. - DOI - PubMed
    1. Li M, Phatnani HP, Guan Z, Sage H, Greenleaf AL, Zhou P. Solution structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction with the hyperphosphorylated C-terminal domain of Rpb1. Proc Natl Acad Sci USA. 2005;102(49):17636–41. doi: 10.1073/pnas.0506350102. - DOI - PMC - PubMed
    1. Rega S, Stiewe T, Chang DI, Pollmeier B, Esche H, Bardenheuer W. et al.Identification of the full-length huntingtin- interacting protein p231HBP/HYPB as a DNA-binding factor. Mol Cell Neurosci. 2001;18(1):68–79. doi: 10.1006/mcne.2001.1004. - DOI - PubMed
    1. Passani LA, Bedford MT, Faber PW, McGinnis KM, Sharp AH, Gusella JF. et al.Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. Hum Mol Genet. 2000;9(14):2175–82. doi: 10.1093/hmg/9.14.2175. - DOI - PubMed

MeSH terms

Substances